Brief: Enlivex Authorizes To Expand Phase II Sepsis Clinical Trial In France, Belgium
04/01/2023 13:24
Jan 4 (Reuters) - Enlivex Therapeutics Ltd ENLV.TA :
* ENLIVEX RECEIVES AUTHORIZATIONS FROM FRENCH AND BELGIAN
REGULATORY AGENCIES TO EXPAND ITS PHASE II SEPSIS CLINICAL TRIAL
INTO FRANCE AND BELGIUM
Source text for Eikon: ID:nGNXXflT9
Further company coverage: ENLV.TA
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enlivex
See all newsBrief: Enlivex Ltd Registers Up To 23,333,333 Ordinary Shares For Resale By Selling Shareholder
Brief: Enlivex Announces Second Regulatory Approval For Phase 2B Trial Of Allocetra In Age-Related Primary Moderate-To-Severe Knee Osteoarthritis
Brief: Enlivex Therapeutics Files For Offering Of Up To $299.6 Mln Of Ordinary Shares
Brief: Enlivex Announces Positive 6-Month Topline Data For Patients with Knee Osteoarthritis
Brief: Enlivex Files Patent for Allocetra Use in Osteoarthritis Treatment